Drug intelligence / Profile preview

irbesartan + hydrochlorothiazide

Development stage
Approved
Lead developer
Sanofi
Modality
Small Molecules
Administration
Oral
01

Overview

Irbesartan + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension) in adults whose blood pressure is not adequately controlled with either component alone. It combines two antihypertensive agents with complementary mechanisms: - **Irbesartan** is an angiotensin II receptor blocker (ARB), specifically antagonizing the AT1 subtype of the angiotensin II receptor. By blocking this receptor, it prevents vasoconstriction and aldosterone-mediated sodium retention caused by angiotensin II, leading to relaxation of blood vessels and reduced blood pressure. - **Hydrochlorothiazide** is a thiazide diuretic that acts on the distal convoluted tubule in the kidney to inhibit sodium reabsorption. This increases urinary excretion of sodium and water, reducing plasma volume and thereby lowering blood pressure. The combination provides an additive antihypertensive effect greater than either drug alone[1][4][8]. The product is available as oral tablets in various strengths.

Brand names
AvalideIrbesartan Hydrochlorothiazide BMSIrbesartan/Hydrochlorothiazide Teva
Other names
irbesartan and hydrochlorothiazidehydrochlorothiazide and irbesartanHCTZ/irbesartan
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)

Beyond the preview

Go deeper on irbesartan + hydrochlorothiazide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on irbesartan + hydrochlorothiazide.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call